This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.

First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Francesco Passamonti, MD, University of Milan, Milan, Italy. Following this, Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, will present initial results from the Phase I/II SANRECO trial (NCT05499013) evaluating divesiran in patients with polycythemia vera (PV). Firas El Chaer, MD, University of Virginia, Charlottesville, VA, and Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, will then give updates on trials exploring novel approaches for patients with relapsed/refractory (R/R) myelofibrosis. Finally, you will hear an update on the BOREAS trial (NCT03662126) from Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.

The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.

Steve Bannon is Heading to Prison